Brief: Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1
25/03/2026 12:29
Sarepta Therapeutics Inc SRPT.O: SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1 SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXICITY FOR FSHD1 AND DM1 SAREPTA THERAPEUTICS INC - PROOF-OF-CONCEPT DATA SHOW SINGLE DOSE OF SRP-1001 AND SRP-1003 REDUCES TARGET PROTEIN OR MRNA SAREPTA THERAPEUTICS INC - MAJORITY OF ADVERSE EVENTS IN STUDIES WERE MILD TO MODERATE AND NOT DOSE DEPENDENT Source text: ID:nBw4rhVGga Further company coverage: SRPT.O
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure